WithdrawnPHASE1, PHASE2NCT02856178

Study on Safety and Pharmacokinetics of Intravenous F901318 for Fungal Prophylaxis in AML Patients

Studying Aspergillosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
F2G Biotech GmbH
Principal Investigator
Oliver Cornely, PhD, MD
University Hospital Cologne
Intervention
F901318(drug)
Eligibility
18 years · All sexes
Timeline
20172017

Collaborators

University Hospital of Cologne

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02856178 on ClinicalTrials.gov

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Aspergillosis

← Back to all trials